Results 151 to 160 of about 4,367 (184)
Journal of Crohn's and ColitisDurable clinical remission, endoscopic healing, and biomarker normalization are key treatment goals for Crohn's disease. The selective anti-interleukin-23 p19 inhibitor risankizumab has demonstrated efficacy and safety in moderately to severely active ...
Remo Panaccione +2 more
exaly +5 more sources
Dermatologic Therapy, 2022 IL‐23‐inhibitors, such as guselkumab and risankizumab, represent the newest class of biologics approved for psoriasis. Phase III trials have shown their efficacy and safety. However, real life data are still scant. to indirectly compare the effectiveness,
Angelo Ruggiero +2 more
exaly +2 more sources
Lancet, The, 2022 BACKGROUND: Risankizumab, an interleukin (IL)-23 p19 inhibitor, was evaluated for safety and efficacy as induction therapy in patients with moderately to severely active Crohn's disease.
Brian Feagan +2 more
exaly +2 more sources
Risankizumab shows high efficacy and maintenance in improvement of response until week 52
Dermatologic Therapy, 2022 Risankizumab has been recently approved for moderate‐to‐severe plaque psoriasis; however, real‐life studies are scarce. Analysis of possible predictor factors of treatment response are limited to body mass index (BMI) and previous biologic experience ...
Simone Ribero +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Hospital Pharmacy, 2019
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy and Therapeutics (P&T) Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy ...
openaire +2 more sources
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy and Therapeutics (P&T) Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy ...
openaire +2 more sources
Canadian Journal of Health Technologies, 2023
CADTH recommends that Skyrizi be reimbursed by public drug plans for the treatment of moderately to severely active Crohn disease (CD) if certain conditions are met. Skyrizi should only be covered to treat adult patients with moderately to severely active CD who do not respond to, stop responding to, or who cannot tolerate conventional or ...
openaire +1 more source
CADTH recommends that Skyrizi be reimbursed by public drug plans for the treatment of moderately to severely active Crohn disease (CD) if certain conditions are met. Skyrizi should only be covered to treat adult patients with moderately to severely active CD who do not respond to, stop responding to, or who cannot tolerate conventional or ...
openaire +1 more source
Risankizumab-rzaa: A New Therapeutic Option for the Treatment of Crohn’s Disease
Annals of Pharmacotherapy, 2023David Choi, Shubha Bhat
exaly